Therapeutic Recombinant Proteins Is Fastest Growing Segment Fueling The Growth Of Recombinant Protein Market

Recombinant Protein Market -
 The global Recombinant Protein Market is estimated to be valued at US$ 3131.37 Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:
Recombinant proteins are genetically engineered proteins that are derived from living organisms and widely used in biotechnology and pharmaceutical industry. They are used for various therapeutic applications due to their high purity, stability and defined composition.

Market key trends:
Therapeutic recombinant proteins have emerged as the largest and fastest growing segment in the recombinant protein market owing to increasing applications in disease treatment and management. Recombinant therapeutic proteins mimic natural human proteins in structure and function and are used to treat chronic diseases such as cancer, anemia, hemophilia, diabetes and others. They either substitute or supplement deficiency of naturally occurring human proteins in the body and help manage disease symptoms effectively with fewer side effects. Some of the major therapeutic recombinant proteins in the market are insulin, growth factors, interferons, colony stimulating factors, monoclonal antibodies and replacement enzymes. The global demand for therapeutic recombinant proteins is expected to rise significantly during the forecast period, driven by rising prevalence of chronic diseases, increasing biopharmaceutical R&D activities and growing awareness about benefits of recombinant therapeutic proteins over conventional drug therapies.
Segment Analysis
Biologics like monoclonal antibodies are the largest and dominating segment in the recombinant protein market accounting for over 35% share. This can be attributed to high usage of monoclonal antibodies for treatment of various chronic diseases like cancer, arthritis etc. due to their high specificity and affinity towards target antigens.

Key Takeaways
The global recombinant protein market analysis is expected to witness high growth, exhibiting CAGR of 11% over the forecast period, due to increasing prevalence of chronic diseases worldwide.

Regional analysis
North America dominated the global recombinant market in 2022 and is expected to continue its dominance over the forecast period. This is attributed to favorable regulatory policies and presence of key players in the region. Asia Pacific is expected to exhibit fastest growth rate owing to rising patient pool, improving healthcare infrastructure and increasing biopharmaceutical industry investments in the region.

Key players

Key players operating in the recombinant protein market include Merck KGaA, OriGene Technologies, Inc., Thermo Fisher Scientific Inc., Feldan Therapeutics, ACROBiosystems, Abcam plc., Randox Laboratories Ltd., SOL GROUP, Proteintech Group, Inc, Planet Biotechnology, Inc., INFINITE ENZYMES, INC., ORF Genetics, GenScript, BTL Biotechno Labs Pvt Ltd., Prospec-Tany Technogene Ltd., BPS Bioscience, Inc., Sino Biological, Cape Bio Pharms, Abnova Corporation, GeNext Genomics

Comments

Popular posts from this blog

Increasing aircrafts deliveries to fuel the growth of Aircraft Radome Market

The Global Cryocooler Market Growth Accelerated By Rising Demand From Aerospace And Military Industries

The Global Dutch Brick Market Growth Accelerated By Increase In Residential Construction